Research compound, not FDA-approved
Selank is a registered Russian medicine and an American research chemical. The molecule is identical. The evidence never left Russia.
Fifty-seven selank papers are indexed in PubMed. Twenty-six are written in Russian. Exactly one carries an author affiliation outside Russia, and it is a review article rather than a study, which puts the count of original non-Russian selank research at zero. Five human studies exist, all Russian, 244 people in total, and not one of their abstracts states a dose. We counted all of it ourselves and published the script that did the counting.
- 0original selank studies from a non-Russian institution, out of 57 papers indexed
- 26of the 57 selank-titled papers are published in Russian
- 6human studies in the evidence table, every one of them Russian
- 26studies in the graded evidence table, species labeled on every row
- 40fetch-verified citations, 95 percent peer-reviewed or government
Online care, from intake to delivery
Selank nasal spray care, made simple
Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Your care plan includes
Everything you need to get started
Encrypted checkout • provider review required • shipping included
- 01Choose your planSelect the supply and refill preference that works for you.
- 02Complete your intakeShare your health history in our private, secure flow.
- 03Provider reviewIf appropriate, your prescription is prepared and shipped.
Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.
Key facts
- StatusResearch compound, not FDA-approved
- Human PK studiesNone published
- Human half-lifeNever measured
- Human bioavailabilityNever measured, by any route including nasal
- MetabolismDegraded in plasma to TKPRP, TKP, RP and GP (rat, tritium label)
- Brain exposureExamined in rat brain tissue after intranasal dosing; no numeric values reported
- Route differenceIn mice, intranasal and intraperitoneal dosing altered different receptor systems, attributed by the authors to pharmacokinetics
- Commonly misquotedPublished half-lives are leu-enkephalin's, not selank's
- ClassSynthetic heptapeptide; tuftsin analog (tuftsin plus Pro-Gly-Pro)
- SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro
- Molecular weight751.9 (C33H57N11O9)
- US statusNot FDA approved for any use; no Drugs@FDA record
- FDA compoundingSelank acetate (TP-7) listed as nominated but withdrawn, with an immunogenicity concern
- Russian statusListed as a registered Russian peptide drug, classified anxiolytic (peer-reviewed source; not verified at the register)
- Selank-titled PubMed papers57, of which 26 are published in Russian
- Non-Russian original studies0 in the PubMed index; the one non-Russian affiliation is a review
- Human studies5 total: 4 in patients, 1 imaging study in healthy volunteers
- People studied244 across all studies with a stated count; largest single study 70
- Randomized controlled efficacy trialsNone located in any readable index
- Registered trials0 on ClinicalTrials.gov
- Human pharmacokineticsNone published: no half-life, clearance or bioavailability for any route
- Established human doseNone. No human study abstract states a dose
- Long-term safetyNo long-term study, toxicology report or adverse-event surveillance located
- SportNot named on the 2026 WADA list; unclear status under the S0 catch-all
Browse by topic
Everything on Selank, organized the way you research it.
Free Selank tools
Practical calculators and references, each scoped and sourced.
All guides
47 in-depth, individually cited guides.
Evidence 13 guides
Safety 13 guides
Comparisons 8 guides
Dosing 8 guides
Sourcing 5 guides
We will tell you if anyone outside Russia ever studies this
One short email if the evidence actually changes. Given the last thirty years, we do not expect to email you often.
